N
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Price:
9.84
CNY
-0.1%
Market Closed
Market Cap:
¥15.9B
Relative Value
The Relative Value of one Nanjing King-friend Biochemical Pharmaceutical Co Ltd stock under the Base Case scenario is 10.76 CNY. Compared to the current market price of 9.84 CNY, Nanjing King-friend Biochemical Pharmaceutical Co Ltd is Undervalued by 9%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
10.76
CNY
Undervaluation 9%
N
Multiples Across Competitors
Competitors Multiples
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
N
|
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
|
15.9B CNY | 4.2 | 24.5 | 20.7 | 20.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
934.5B USD | 14.3 | 45.3 | 30.5 | 32.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.6B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
256.6B CHF | 4.2 | 19.9 | 11.8 | 13.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.5B GBP | 5.1 | 29.4 | 16.3 | 22.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
235B CHF | 5.4 | 21.6 | 13.3 | 17.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
285.6B USD | 4.4 | 15.6 | 9.7 | 11.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.9 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.3B USD | 2.4 | 19.5 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD | 2.5 | 17.1 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
